vs

Side-by-side financial comparison of EXACT SCIENCES CORP (EXAS) and GLOBALFOUNDRIES Inc. (GFS). Click either name above to swap in a different company.

GLOBALFOUNDRIES Inc. is the larger business by last-quarter revenue ($1.7B vs $878.4M, roughly 1.9× EXACT SCIENCES CORP). GLOBALFOUNDRIES Inc. runs the higher net margin — 14.8% vs -9.8%, a 24.5% gap on every dollar of revenue. On growth, EXACT SCIENCES CORP posted the faster year-over-year revenue change (23.1% vs -2.9%). Over the past eight quarters, EXACT SCIENCES CORP's revenue compounded faster (17.4% CAGR vs -4.3%).

Exact Sciences Corporation is an American molecular diagnostics company based in Madison, Wisconsin, specializing in the detection of early-stage cancers. The company provides products for the detection and prevention of colorectal cancer, including Cologuard, the first stool DNA test for colorectal cancer, along with additional screening and precision oncological tests for other types of cancer.

GlobalFoundries Inc. is a multinational semiconductor contract manufacturing and design company domiciled in the Cayman Islands and headquartered in Malta, New York. Created by the divestiture of the manufacturing arm of AMD in March 2009, the company was privately owned by Mubadala Investment Company, a sovereign wealth fund of the United Arab Emirates, until an initial public offering (IPO) in October 2021. Mubadala remains the majority owner of the company with an 82% stake.

EXAS vs GFS — Head-to-Head

Bigger by revenue
GFS
GFS
1.9× larger
GFS
$1.7B
$878.4M
EXAS
Growing faster (revenue YoY)
EXAS
EXAS
+26.1% gap
EXAS
23.1%
-2.9%
GFS
Higher net margin
GFS
GFS
24.5% more per $
GFS
14.8%
-9.8%
EXAS
Faster 2-yr revenue CAGR
EXAS
EXAS
Annualised
EXAS
17.4%
-4.3%
GFS

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
EXAS
EXAS
GFS
GFS
Revenue
$878.4M
$1.7B
Net Profit
$-86.0M
$249.0M
Gross Margin
70.1%
24.8%
Operating Margin
-9.4%
11.6%
Net Margin
-9.8%
14.8%
Revenue YoY
23.1%
-2.9%
Net Profit YoY
90.1%
39.9%
EPS (diluted)
$-0.45
$0.44

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXAS
EXAS
GFS
GFS
Q4 25
$878.4M
Q3 25
$850.7M
$1.7B
Q2 25
$811.1M
$1.7B
Q1 25
$706.8M
$1.6B
Q4 24
$713.4M
Q3 24
$708.7M
$1.7B
Q2 24
$699.3M
$1.6B
Q1 24
$637.5M
$1.5B
Net Profit
EXAS
EXAS
GFS
GFS
Q4 25
$-86.0M
Q3 25
$-19.6M
$249.0M
Q2 25
$-1.2M
$228.0M
Q1 25
$-101.2M
$211.0M
Q4 24
$-864.6M
Q3 24
$-38.2M
$178.0M
Q2 24
$-15.8M
$155.0M
Q1 24
$-110.2M
$134.0M
Gross Margin
EXAS
EXAS
GFS
GFS
Q4 25
70.1%
Q3 25
68.6%
24.8%
Q2 25
69.3%
24.2%
Q1 25
70.8%
22.4%
Q4 24
69.0%
Q3 24
69.4%
23.8%
Q2 24
69.8%
24.2%
Q1 24
70.0%
25.4%
Operating Margin
EXAS
EXAS
GFS
GFS
Q4 25
-9.4%
Q3 25
-3.0%
11.6%
Q2 25
-0.3%
11.6%
Q1 25
-13.6%
9.5%
Q4 24
-122.8%
Q3 24
-5.6%
10.6%
Q2 24
-3.8%
9.5%
Q1 24
-16.7%
9.5%
Net Margin
EXAS
EXAS
GFS
GFS
Q4 25
-9.8%
Q3 25
-2.3%
14.8%
Q2 25
-0.1%
13.5%
Q1 25
-14.3%
13.3%
Q4 24
-121.2%
Q3 24
-5.4%
10.2%
Q2 24
-2.3%
9.5%
Q1 24
-17.3%
8.7%
EPS (diluted)
EXAS
EXAS
GFS
GFS
Q4 25
$-0.45
Q3 25
$-0.10
$0.44
Q2 25
$-0.01
$0.41
Q1 25
$-0.54
$0.38
Q4 24
$-4.69
Q3 24
$-0.21
$0.32
Q2 24
$-0.09
$0.28
Q1 24
$-0.60
$0.24

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXAS
EXAS
GFS
GFS
Cash + ST InvestmentsLiquidity on hand
$964.7M
$2.0B
Total DebtLower is stronger
Stockholders' EquityBook value
$2.4B
$11.8B
Total Assets
$5.9B
$16.7B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXAS
EXAS
GFS
GFS
Q4 25
$964.7M
Q3 25
$1.0B
$2.0B
Q2 25
$858.4M
$1.8B
Q1 25
$786.2M
$1.6B
Q4 24
$1.0B
Q3 24
$1.0B
$2.3B
Q2 24
$946.8M
$2.2B
Q1 24
$652.1M
$2.2B
Stockholders' Equity
EXAS
EXAS
GFS
GFS
Q4 25
$2.4B
Q3 25
$2.5B
$11.8B
Q2 25
$2.5B
$11.5B
Q1 25
$2.4B
$11.1B
Q4 24
$2.4B
Q3 24
$3.2B
$11.6B
Q2 24
$3.2B
$11.3B
Q1 24
$3.1B
$11.3B
Total Assets
EXAS
EXAS
GFS
GFS
Q4 25
$5.9B
Q3 25
$5.9B
$16.7B
Q2 25
$5.8B
$16.8B
Q1 25
$5.7B
$16.5B
Q4 24
$5.9B
Q3 24
$6.7B
$18.1B
Q2 24
$6.7B
Q1 24
$6.4B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXAS
EXAS
GFS
GFS
Operating Cash FlowLast quarter
$151.7M
$595.0M
Free Cash FlowOCF − Capex
$120.4M
FCF MarginFCF / Revenue
13.7%
Capex IntensityCapex / Revenue
3.6%
Cash ConversionOCF / Net Profit
2.39×
TTM Free Cash FlowTrailing 4 quarters
$356.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXAS
EXAS
GFS
GFS
Q4 25
$151.7M
Q3 25
$219.9M
$595.0M
Q2 25
$89.0M
$431.0M
Q1 25
$30.8M
$331.0M
Q4 24
$47.1M
Q3 24
$138.7M
$375.0M
Q2 24
$107.1M
$402.0M
Q1 24
$-82.3M
$488.0M
Free Cash Flow
EXAS
EXAS
GFS
GFS
Q4 25
$120.4M
Q3 25
$190.0M
Q2 25
$46.7M
Q1 25
$-365.0K
Q4 24
$10.7M
Q3 24
$112.6M
Q2 24
$71.2M
Q1 24
$-120.0M
FCF Margin
EXAS
EXAS
GFS
GFS
Q4 25
13.7%
Q3 25
22.3%
Q2 25
5.8%
Q1 25
-0.1%
Q4 24
1.5%
Q3 24
15.9%
Q2 24
10.2%
Q1 24
-18.8%
Capex Intensity
EXAS
EXAS
GFS
GFS
Q4 25
3.6%
Q3 25
3.5%
Q2 25
5.2%
Q1 25
4.4%
Q4 24
5.1%
Q3 24
3.7%
Q2 24
5.1%
Q1 24
5.9%
Cash Conversion
EXAS
EXAS
GFS
GFS
Q4 25
Q3 25
2.39×
Q2 25
1.89×
Q1 25
1.57×
Q4 24
Q3 24
2.11×
Q2 24
2.59×
Q1 24
3.64×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXAS
EXAS

Screening$695.1M79%
Precision Oncology$183.2M21%

GFS
GFS

Smart Mobile Devices$752.0M45%
Automotive$306.0M18%
Home And Industrial Io T$258.0M15%
Goods Or Services Transferred Over Time$198.0M12%
Communications Infrastructure Datacenter$175.0M10%

Related Comparisons